The agreement gives Merck exclusive ex-US rights to ompenaclid – an oral inhibitor of the creatine transport channel SLC6A8 – as well as options to co-develop and co-promote the drug in the US ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback